{"entity":{"id":"sandra-swain","kind":"person","name":"Sandra M. Swain","aka":[],"tldr":"Led CLEOPATRA, which showed dual HER2 blockade with pertuzumab gives an unprecedented 16-month survival gain in metastatic disease.","summary":"Sandra Swain was principal investigator of CLEOPATRA, the trial establishing pertuzumab plus trastuzumab and docetaxel as first-line therapy for HER2-positive metastatic breast cancer with a median survival of 56 months. She has led NSABP trials, chaired ASCO, and published extensively on anthracycline cardiotoxicity. Her current work covers HER2-directed therapy sequencing and disparities in trial access.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Sandra_M._Swain","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Swain%20SM%5BAuthor%5D%20pertuzumab"}],"tags":["breast","her2","trialist"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["monoclonal-antibody","cardio-oncology"],"targets":["her2"],"drugs":["trastuzumab"],"companies":[],"institutions":["georgetown-lombardi"],"pathways":[],"terms":[],"trials":["cleopatra"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Associate Dean for Research Development, Georgetown University Medical Center","institutionId":"georgetown-lombardi","specialisms":["HER2-positive breast cancer","Anti-HER2 combinations","Cardio-oncology","Inflammatory breast cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Swain%20SM%5BAuthor%5D%20pertuzumab"}],"papers":[{"title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer (CLEOPATRA)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1413513"},{"title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","journal":"NEJM","year":2012,"doi":"10.1056/NEJMoa1113216"}],"orcid":"0000-0002-1320-3830"},"route":"/people/sandra-swain/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"technology":[{"id":"cardio-oncology","kind":"technology","name":"Cardio-oncology","route":"/technologies/cardio-oncology/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"institution":[{"id":"georgetown-lombardi","kind":"institution","name":"Georgetown Lombardi Comprehensive Cancer Center","route":"/institutions/georgetown-lombardi/"}],"trial":[{"id":"cleopatra","kind":"trial","name":"CLEOPATRA","route":"/trials/cleopatra/"}]}}